The European Pharmacopoeia (Ph. Eur.) is a single reference work of official standards for medicines in Europe.
It provides a legal and scientific basis for quality control during the development, production and marketing processes of medical products.
The Ph. Eur. main volume and supplements detail the composition of medicines, as well as the tests, raw materials used in production and the intermediates of medicine synthesis.
European Pharmacopoeia monographs and other texts are designed to be appropriate to the needs of:
- regulatory authorities
- those engaged in the quality control of medicinal products and their constituents
- manufacturers of medicinal products and their individual components.
Ph. Eur. monographs give quality standards for all the main medicines used in Europe and outline preparations for
- Pharmaceutical use of chemical, animal, human or herbal origin
- Biologicals, blood and plasma derivatives, vaccines and radiopharmaceutical preparations.
The European Pharmacopoeia is supplied as a subscription only to ensure that subscribers receive all three issues of their purchase. Print supplements are non-cumulative and therefore all previous issues of an edition are required. Electronic supplements are completely cumulative and only the current edition is required.
The 11th Edition of the Ph. Eur. was released in July 2022 and will be updated with eight periodic supplements over the following years (11.1 to 11.8).
Available to buy now from TSO
Click on the product links below or, for more details, please contact our team on +44 (0)333 202 5070 or email: email@example.com.
Publication and implementation dates
|EP 11.0 Main Edition||July 2022||1 January 2023|
|EP Volume 11.1||October 2022||1 April 2023|
|EP Volume 11.2||January 2022||1 July 2023|
|EP Volume 11.3||July 2023||1 January 2024|
|EP Volume 11.4||October 2023||1 April 2024|
|EP Volume 11.5||January 2023||1 July 2024|
|EP Volume 11.6||July 2024||1 January 2025|
|EP Volume 11.7||October 2024||1 April 2025|
|EP Volume 11.8||January 2024||1 July 2025|